Toronto Confirms New Mpox Variant Cases
Toronto has confirmed two travel-related cases of the new mpox variant, known as Clade Ib. This development raises public health concerns as the variant is linked to outbreaks in Central and Eastern Africa.
As of the end of 2025, a total of 155 mpox cases had been confirmed in Toronto, indicating a growing concern regarding the virus’s spread. Symptoms of mpox include fever, chills, headache, muscle aches, fatigue, and rash, which can significantly impact affected individuals.
The mpox vaccine is available for eligible residents through clinics and community partners, and it is provided free of charge, with or without a health card. Individuals who have received two doses of the mpox vaccine do not need additional vaccinations, which may help mitigate the spread of the virus.
Despite the emergence of Clade Ib, treatment guidance for mpox remains unchanged. Health officials emphasize that the current risk appears contained, but they acknowledge that headlines can shift sentiment quickly.
Clade Ib is considered more severe than the previously identified Clade 2b, which was reported in a few cases in Toronto in 2022. Both variants can cause painful skin lesions, fever, and other flu-like symptoms, necessitating ongoing vigilance from public health authorities.
The virus can be transmitted through close, intimate, or sexual contact with an infected person, highlighting the importance of awareness and preventive measures in the community.
Toronto Public Health is actively monitoring the situation and providing updates as necessary. Details remain unconfirmed regarding the broader implications of this new variant.
